Hostname: page-component-6766d58669-mzsfj Total loading time: 0 Render date: 2026-05-18T03:53:08.346Z Has data issue: false hasContentIssue false
  • English
  • Français

GSTT1, GSTM1, GSTM3 and NAT2 polymorphisms in laryngeal squamous cell carcinoma in a Greek population

Published online by Cambridge University Press:  19 November 2009

M Chatzimichalis ,
J Xenellis ,
A Tzagaroulakis ,
P Sarof ,
K Banis ,
M Gazouli  and
A Bibas
M Chatzimichalis
Affiliation:
Department of Otolaryngology Head and Neck Surgery, Metaxa Anticancer Hospital, Piraeus, Greece
J Xenellis
Affiliation:
Department of Otolaryngology Head and Neck Surgery, School of Medicine, University of Athens, Greece
A Tzagaroulakis
Affiliation:
Department of Otolaryngology Head and Neck Surgery, School of Medicine, University of Athens, Greece
P Sarof
Affiliation:
Department of Otolaryngology Head and Neck Surgery, Metaxa Anticancer Hospital, Piraeus, Greece
K Banis
Affiliation:
Department of Otolaryngology Head and Neck Surgery, Metaxa Anticancer Hospital, Piraeus, Greece
M Gazouli*
Affiliation:
Department of Biology, School of Medicine, University of Athens, Greece
A Bibas
Affiliation:
Department of Otolaryngology Head and Neck Surgery, School of Medicine, University of Athens, Greece
*
Address for correspondence: Dr Maria Gazouli, Department of Biology, School of Medicine, University of Athens, Michalakopoulou 176, 11527 Athens, Greece. E-mail: mgazouli@med.uoa.gr
Get access Rights & Permissions [Opens in a new window]

Abstract

Objective:

It is well known that laryngeal squamous cell carcinoma is strongly related to tobacco and alcohol consumption. Accumulating evidence suggests that alterations of detoxification enzymes, such as glutathione S-transferases and N-acetyltransferases, influence the risk of cancers associated with tobacco smoke and alcohol.

Methods:

This was a retrospective case–control study. The study group consisted of 88 Greek patients with laryngeal squamous cell carcinoma; there were also 102 control subjects. Frequencies of the genotypes GSTT1, GSTM1, GSTM3 and NAT2 were evaluated by polymerase chain reaction restriction fragment polymorphism.

Results:

The distribution of overall genotypes was 55.68 per cent rapid acetylator and 44.32 per cent slow acetylator in patients, and 36.27 per cent rapid acetylator and 63.72 per cent slow acetylator in controls. The odds ratio for rapid acetylator status in cases versus controls was 2.207 (95 per cent confidence interval 1.23–3.95, p = 0.0087).

Conclusion:

This study demonstrated a significant relationship between rapid acetylator genotypes and laryngeal squamous cell carcinoma in a Greek population.

Keywords

Laryngeal Squamous Cell CarcinomaGene PolymorphismsGSTT1GSTM1GSTM3NAT2

Information

Type
Main Article
Information
The Journal of Laryngology & Otology , Volume 124 , Issue 3 , March 2010 , pp. 318 - 323
Copyright
Copyright © JLO (1984) Limited 2009

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Article purchase

Temporarily unavailable

References

1Cann, CI, Fried, MP, Rothman, KJ. Epidemiology of squamous cell cancer of the head and neck. Otolaryngol Clin North Am 1985;18:367–88CrossRefGoogle ScholarPubMed
2Muscat, JE, Wynder, EL. Tobacco, alcohol, asbestos, and occupational risk factors for laryngeal cancer. Cancer 1992;69:2244–513.0.CO;2-O>CrossRefGoogle ScholarPubMed
3Hein, DW, Doll, MA, Fretland, AJ, Leff, MA, Webb, SJ, Xiao, GH et al. Molecular genetics and epidemiology of the NAT1 and NAT2 acetylation polymorphisms. Cancer Epidemiol Biomarkers Prev 2000;9:29–42Google ScholarPubMed
4Ford, JG, Li, Y, O'Sullivan, MM, Demopoulos, R, Garte, S, Taioli, E et al. Glutathione S-transferase M1 polymorphism and lung cancer risk in African-Americans. Carcinogenesis 2000;21:1971–5CrossRefGoogle ScholarPubMed
5To-Figueras, J, Gene, M, Gomez-Catalan, J, Galán, MC, Fuentes, M, Ramón, JM et al. Glutathione S-transferase M1 (GSTM1) and T1 (GSTT1) polymorphisms and lung cancer risk among northwestern Mediterraneans. Carcinogenesis 1997;18:1529–33CrossRefGoogle ScholarPubMed
6Inskip, A, Elexperu-Camiruaga, J, Buxton, N, Dias, PS, MacIntosh, J, Campbell, D et al. Identification of polymorphism at the glutathione S-transferase, GSTM3 locus: evidence for linkage with GSTM1*A. Biochem J 1995;312:713–16CrossRefGoogle ScholarPubMed
7Butcher, NJ, Boukouvala, S, Sim, E, Minchin, RF. Pharmacogenetics of the arylamine N-acetyltransferases. Pharmacogenomics J 2002;2:30–42CrossRefGoogle ScholarPubMed
8Henning, S, Cascorbi, I, Munchow, B, Jahnke, V, Roots, I. Association of arylamine N-acetyltransferases NAT1 and NAT2 genotypes to laryngeal cancer risk. Pharmacogenetics 1999;9:103–11CrossRefGoogle ScholarPubMed
9Morita, S, Yano, M, Tsujinaka, T, Akiyama, Y, Taniguchi, M, Kaneko, K et al. Genetic polymorphisms of drug-metabolizing enzymes and susceptibility to head-and-neck squamous-cell carcinoma. Int J Cancer 1999;80:685–83.0.CO;2-W>CrossRefGoogle ScholarPubMed
10Drozdz, M, Gierek, T, Jendryczko, A, Pilch, J, Piekarska, J. N-acetyltransferase phenotype of patients with cancer of the larynx. Neoplasma 1987;34:481–4Google ScholarPubMed
11To-Figueras, J, Gene, M, Gomez-Catalan, J, Galan, C, Firvida, J, Fuentes, M et al. Glutathione-S-Transferase M1 and codon 72 p53 polymorphisms in a northwestern Mediterranean population and their relation to lung cancer susceptibility. Cancer Epidemiol Biomarkers Prev 1996;5:337–42Google Scholar
12Doll, MA, Fretland, AJ, Deitz, AC, Hein, DW. Determination of human NAT2 acetylator genotype by restriction fragment-length polymorphism and allele-specific amplification. Anal Biochem 1995;231:413–20CrossRefGoogle ScholarPubMed
13Cascorbi, I, Roots, I. Pitfalls in N-acetyltransferase 2 genotyping. Pharmacogenetics 1999;9:123–7CrossRefGoogle ScholarPubMed
14Hein, DW, Doll, MA, Rustan, TD, Gray, K, Feng, Y, Ferguson, RJ et al. Metabolic activation and deactivation of arylamine carcinogens by recombinant human NAT1 and polymorphic NAT2 acetyltransferases. Carcinogenesis 1993;14:1633–8CrossRefGoogle ScholarPubMed
15Meyer, UA, Zanger, UM. Molecular mechanisms of genetic polymorphisms of drug metabolism. Annu Rev Pharmacol Toxicol 1997;37:269–6CrossRefGoogle ScholarPubMed
16Trizna, Z, Clayman, GL, Spitz, MR, Briggs, KL, Goepfert, H. Glutathione s-transferase genotypes as risk factors for head and neck cancer. Am J Surg 1995;170:499–501CrossRefGoogle ScholarPubMed
17Gajecka, M, Rydzanicz, M, Jaskula-Sztul, R, Kujawski, M, Szyfter, W, Szyfter, K. CYP1A1, CYP2D6, CYP2E1, NAT2, GSTM1 and GSTT1 polymorphisms or their combinations are associated with the increased risk of the laryngeal squamous cell carcinoma. Mutat Res 2005;574:112–23CrossRefGoogle ScholarPubMed
18Jahnke, V, Strange, R, Matthias, C, Fryer, A. Glutathione S-transferase and cytochrome P450 genotypes as risk factors for laryngeal carcinoma. Eur Arch Otorhinolaryngol 1997;254:47–9CrossRefGoogle ScholarPubMed
19Blum, M, Demierre, A, Grant, DM, Heim, M, Meyer, UA. Molecular mechanism of slow acetylation of drugs and carcinogens in humans. Proc Natl Acad Sci U S A 1991;88:5237–41CrossRefGoogle ScholarPubMed
20Cascorbi, I, Brockmoller, J, Mrozikiewicz, PM, Bauer, S, Loddenkemper, R, Roots, I. Homozygous rapid arylamine N-acetyltransferase (NAT2) genotype as a susceptibility factor for lung cancer. Cancer Res 1996;56:3961–6Google ScholarPubMed